Triangle formation near apex. Break up gives buy signalBonesupport reported some very promising results in the latest report, but the market has not yet, in my opinion, realised its value. It actually gave no effect at all on the stock.
ABG sundal Collier recently raised the target price to 53kr from 30kr.
ABG Sundal Collier höjer riktkursen för Bonesupport till 53 kronor från 30 kronor. Rekommendationen köp upprepas. Det framgår av en analys.
Carnegie is acting as sell block at the moment but when they loosen their sell pressure, the revaluation can begin.
A triangle formation with a raising introduction is getting closer to its apex and if the stock breaks the triangle roof, a price of 46kr is justified.
Overall there is both technical and fundamental support at this level (30kr-35kr) and is in my opinion undervalued.
---
This is not a recommendation, but rather my speculations and personal thoughts.
You should always make your own analysis before buying any stock.
---
Xbrane moving out of DowntrendXbrane Biopharma AB is a biotechnology company which develops and manufactures biosimilars. Xbrane has a patented protein production platform and world-leading expertise within biosimilar development.
Xbrane’s headquarter is located in Solna, just outside of Stockholm, and the company has research and development facilities in Sweden and in Italy.
Biosimilars are approved pharmaceuticals that are similar to a biological reference product in terms of quality, safety and efficacy. They are approved in highly regulated markets such as the EU and the US.
Biosimilars are so far typically launched with a 20-40% discount vs. the reference biological drug improving significantly the accessibility of the treatments and generating massive cost savings for private and public payors.
Xlucane - Lucentis® - Phase 3 - Global annual sales € 3.2 billion
phase III trial was initiated Q1 2019 with primary aim to evaluate comparative efficacy in terms of change in visual acuity 8 weeks after initiation of treatment. Xbrane has acceptance for the study design from both EMA and FDA. The target is to launch the product upon patent expiration in Europe beginning of 2022.
Preclinical drugs
Spherotide - Decapeptyl®
Xcimzane - Cimzia® - Global annual sales € 1.4 billion
Xoncane - Oncaspar®
Xbrane has entered into a co-development agreement for Xlucane with the German generic/biosimilar company STADA. Under the agreement Xbrane is responsible for development of the product and STADA for sales and marketing. Development expenses and profits generated from sales of the product are shared 50/50.
L/S Swedish Equities Pairs TradeConsumer Defensive / Consumer Cyclical
30/12/2019 Close
Long: ESSITY_B Current Price SEK: 301.80
Short: WESC_AB Current Price SEK: 0.0046
ESSITY / WESC spread Entry Range: 65608.70
ESSITY / WESC spread Hard Stop: 59076.70 (10%)
ESSITY / WESC spread Soft Target: 85374.00 (30%)
BETA hedge
For every SEK 1.00 Long of ESSITY_B
SEK 9.00 Short of WESC_AB
*Build you position in two stages enter with 50% of desired exposure.
*+add too the position on a breakout or at the soft target.
*Hedge your currency exposure, unless you have a view on SEK.
*HIGH RISK trade.
Essity: Consumer Defensive (Manufacture Tissues, Toilet paper & other hygiene products) Strong fundamentals, very defensive and predictable earnings with consistent global demand, outperformed all of its competitors in 2019.
*Market Cap = 212B
*EPS = 14.10
ESSITY_B Consensus Jan 2020 =F1 Jan 2021 =F2
F1 P/E: 20.10x
F2 P/E: 17.60x
F1 Earnings Growth: 22.38%
F2 Earnings Growth: 6.70%
F1 Sales Growth: 2.70%
F2 Sales Growth: 3.00%
F1 PEG: 0.89
F2 PEG: 2.62
Risk: Reflation of the global economy, and solid resolution of political tensions. And therefore a full risk on scenario and defensive stock underperformance.
Wesc: Consumer Cyclical (Trades Apparel & related products, under it brand name WESC) Weak fundamentals, very cyclical and “polluting” as it’s fast low quality fashion. Loss making. In desperate need of a turn around, I feel the business will not attract new talent (As the brand is notoriously NOT cool for millennials and gen z) and isn’t worth turning around as a brand, also no analyst and very hard to find relevant financial information in for the company.
*Market cap = 22M
*EPS = -0.0150
Risk: Merger, acquisition or turnaround. Otherwis I’d be happy to keep this position on for the foreseeable future.
*KEEP YOUR POSITION SIZE SMALL*
This is a risky pairs trade as WESC could get bought out, or turned around and go to infinity, but I’m betting against that.
LONG High quality Swedish Consumer Staple.
SHORT Low quality Swedish Consumer Cyclical.
Meeting long term resistance line on RSIAs seen on the indicator: "RSI" Maha has a very clear resistance line. As of today, 29/12/2019, I find it fitting for a potential retracement which also is because of the Fibonacci Retracement 0.618 line causing resistance. MAHA is still in a very strong uptrend with a massive primary trend of about 35%. I expect a rather small retracement without selling my position unless I see a closing price under 22.5
Let's buy paintI-tech seems like it has reversed it's trend. Volume climax to the downside was bought up quickly (probably early investor who sold) and wave 2 text-book bounce on the .618 fibonacci. Start to scale in now or wait for Wave 4 (ABC) to play out. Could do 3x in one 8-12 months. Trade setup is invalid under Wave 2.